These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28778710)

  • 21. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.
    Pattanaik D; Postlethwaite AE
    Discov Med; 2010 Aug; 10(51):161-7. PubMed ID: 20807477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc).
    Valentini G
    Autoimmun Rev; 2015 Mar; 14(3):210-3. PubMed ID: 25461837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality].
    Becker MO; Müller-Ladner U; Riemekasten G
    Z Rheumatol; 2010 Jun; 69(4):310-7. PubMed ID: 20490516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of environmental risk factors in systemic sclerosis.
    De Martinis M; Ciccarelli F; Sirufo MM; Ginaldi L
    Expert Rev Clin Immunol; 2016; 12(4):465-78. PubMed ID: 26610037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenic autoantibodies in systemic sclerosis.
    Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
    Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines.
    Reed J; Pope J
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S40-6. PubMed ID: 26121522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten years of a systemic sclerosis clinic in a tertiary referral centre - insights and future directions.
    Martins P; Dourado E; Fonseca JE; Cordeiro I; Romão VC; Resende C
    Acta Reumatol Port; 2021; 46(3):257-265. PubMed ID: 34628459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into CD4(+) T cell abnormalities in systemic sclerosis.
    Liu M; Wu W; Sun X; Yang J; Xu J; Fu W; Li M
    Cytokine Growth Factor Rev; 2016 Apr; 28():31-6. PubMed ID: 26724976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
    Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
    Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lung impairment in systemic sclerosis].
    Knoop H; Arinir U; Kreuter A; Walther JW; Schultze-Werninghaus G; Rohde G
    Pneumologie; 2009 Sep; 63(9):497-507. PubMed ID: 19708006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Connective tissue diseases: New evidence-based guidelines for treating SSc.
    Pope JE
    Nat Rev Rheumatol; 2009 Jun; 5(6):300-2. PubMed ID: 19491908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
    Thachil J
    Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Immunol; 2016 Oct; 197(8):3018-3028. PubMed ID: 27613696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis.
    Chora I; Guiducci S; Manetti M; Romano E; Mazzotta C; Bellando-Randone S; Ibba-Manneschi L; Matucci-Cerinic M; Soares R
    Autoimmun Rev; 2015 Apr; 14(4):314-22. PubMed ID: 25485941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetics of systemic sclerosis.
    Bossini-Castillo L; López-Isac E; Mayes MD; Martín J
    Semin Immunopathol; 2015 Sep; 37(5):443-51. PubMed ID: 26032405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.